TuHURA (HURA) CEO falls below 5% ownership after new shares

Rhea-AI Filing Summary

TuHURA Biosciences, Inc. (HURA) discloses that its President, Chief Executive Officer and director, James A. Bianco, M.D., now beneficially owns 3,085,519 shares of common stock, or 4.6% of the company’s outstanding common stock. This total includes 2,173,307 shares and 912,212 shares issuable upon option exercises within 60 days.

Dr. Bianco’s ownership percentage fell below 5% solely because TuHURA issued 1,878,287 additional shares of common stock to Parkview Holdings One LLC under an April 21, 2026 Fee Letter, increasing total shares outstanding to 65,758,360 as of August 18, 2026. He reports no purchases or sales of TuHURA stock in connection with this change and continues in his executive and director roles. This amendment serves as an exit filing for his more-than-5% beneficial owner status.

Key Figures

Beneficial ownership: 3,085,519 shares of Common Stock Direct common shares: 2,173,307 shares of Common Stock Options exercisable within 60 days: 912,212 shares of Common Stock issuable upon exercise +3 more

6 metrics

Beneficial ownership 3,085,519 shares of Common Stock Shares beneficially owned by James A. Bianco, M.D. as of the amendment date

Direct common shares 2,173,307 shares of Common Stock Portion of Dr. Bianco’s beneficial ownership held as common stock

Options exercisable within 60 days 912,212 shares of Common Stock issuable upon exercise Options held by Dr. Bianco that are exercisable within 60 days

Ownership percentage 4.6% Percent of TuHURA common stock beneficially owned by Dr. Bianco

Shares outstanding 65,758,360 shares of Common Stock TuHURA shares outstanding as of August 18, 2026 used for the ownership calculation

Shares issued to Parkview Holdings One LLC 1,878,287 shares of Common Stock Shares issued under the April 21, 2026 Fee Letter causing dilution

Key Terms

beneficially owned, sole voting and dispositive power, Fee Letter, beneficial owner of more than five percent, +2 more

6 terms

beneficially owned financial

"As of the date hereof, the Reporting Person beneficially owned 3,085,519 shares"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

sole voting and dispositive power financial

"the Reporting Person has sole voting and dispositive power over 3,085,519 shares"

Fee Letter financial

"shares of Common Stock issued as a result of the Fee Letter"

beneficial owner of more than five percent regulatory

"the Reporting Person ceased to be the beneficial owner of more than five percent"

Rule 13d-3(d)(1)(i) regulatory

"calculated in accordance with Rule 13d-3(d)(1)(i) promulgated , as amended"

exit filing regulatory

"constitutes an exit filing for the Reporting Person"

FAQ

How many HURA shares does James A. Bianco, M.D. currently beneficially own?

He beneficially owns 3,085,519 shares of TuHURA Biosciences common stock, consisting of 2,173,307 shares plus 912,212 shares issuable upon the exercise of options that are exercisable within 60 days of the relevant date.

What percentage of TuHURA Biosciences (HURA) does James A. Bianco own after this amendment?

James A. Bianco beneficially owns approximately 4.6% of TuHURA Biosciences’ outstanding common stock, based on 65,758,360 shares outstanding as of August 18, 2026, calculated in accordance with Rule 13d-3(d)(1)(i).

Why did James A. Bianco’s beneficial ownership in HURA fall below 5%?

His percentage fell below 5% because TuHURA issued 1,878,287 additional common shares to Parkview Holdings One LLC under an April 21, 2026 Fee Letter, increasing total shares outstanding and diluting his percentage without any transaction by him.

Did James A. Bianco buy or sell any TuHURA (HURA) shares in connection with this ownership change?

No. The amendment states that the change in his beneficial ownership percentage resulted from the company’s issuance of shares to Parkview Holdings One LLC, and that no funds were used or received by him and no acquisitions or dispositions by him are reported.

What portion of James A. Bianco’s HURA holdings are stock options?

Out of his 3,085,519 beneficially owned shares, 912,212 are shares of common stock issuable upon the exercise of options that are exercisable within 60 days of the stated date; the remaining 2,173,307 shares are held as common stock.

Does James A. Bianco still have reporting obligations as a more-than-5% owner of HURA?

No. As of August 18, 2026, he ceased to be a beneficial owner of more than 5% of TuHURA’s common stock, and this amendment is described as the final and exit filing for his Section 13(d) reporting obligations regarding this class.

What roles does James A. Bianco currently hold at TuHURA Biosciences (HURA)?

He is identified as the President and Chief Executive Officer and a director of TuHURA Biosciences, Inc., and the amendment states that he continues to serve in these positions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/28/2026 - 06:02 PM Accepted by SEC EDGAR 08/28/2026 - 06:01 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 1)

TuHURA Biosciences, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

898920103

(CUSIP Number)

James A. Bianco, M.D.
TuHURA Biosciences, Inc., 10500 University Drive, Suite 110
Tampa, FL, 33612
(813) 875-6600

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

08/18/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

schemaVersion:

SCHEDULE 13D

CUSIP Number(s): 898920103

1

Name of reporting person

James A. Bianco, M.D.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 3,085,519.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 3,085,519.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

3,085,519.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

4.6 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

Includes (i) 2,173,307 shares of common stock, par value $0.001 (the "Common Stock") of TuHURA Biosciences, Inc., a Nevada corporation (the "Issuer"), and (ii) 912,212 options to purchase Common Stock held directly by Dr. Bianco exercisable within 60 days after the date hereof. Percent of class is calculated based on 65,758,360 shares of Common Stock outstanding as of August 18, 2026. The percentage of ownership reported was calculated in accordance with Rule 13d-3(d)(1)(i) promulgated under the Securities Exchange Act of 1934, as amended.

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock, par value $0.001 per share
(b)	Name of Issuer: TuHURA Biosciences, Inc.
(c)	Address of Issuer's Principal Executive Offices: 10500 UNIVERSITY CENTER DR., SUITE 110, TAMPA, FLORIDA , 33612.
Item 1 Comment: This Amendment No. 1 to Schedule 13D (this "Amendment") amends and supplements the Schedule 13D originally filed with the SEC on October 25, 2024 (the "Original Schedule 13D") relating to Common Stock of the Issuer. Capitalized terms used but not defined herein have the meanings ascribed to them in the Original Schedule 13D. All references in the Original Schedule 13D and this Amendment shall be deemed to refer to the Original Schedule 13D as amended and supplemented by this Amendment. James A. Bianco, M.D. (the "Reporting Person") is filing this Amendment to report that his beneficial ownership percentage in the Issuer has fallen below 5% as a result of the issuance of 1,878,287 shares of Common Stock to Parkview Holdings One LLC ("Parkview") pursuant to that certain Fee Letter, dated April 21, 2026, between the Issuer and Parkview (the "Fee Letter"). This Amendment does not reflect or report any transactions in the Issuer's Common Stock by the Reporting Person and is being filed solely to report the reduction in the Reporting Person's beneficial ownership percentage as a result of the Issuer's issuance of shares of Common Stock to a party that is not an affiliate of the Reporting Person. The filing of this Amendment represents the final amendment to the Original Schedule 13D and constitutes an exit filing for the Reporting Person.
Item 2.	Identity and Background
(a)	This Amendment is being filed by the Reporting Person.
(b)	The address of the Reporting Person is c/o TuHURA Biosciences, Inc., 10500 University Drive, Suite 110, Tampa, Florida 33612.
(c)	The Reporting Person is the President and Chief Executive Officer and a director of the Issuer.
(d)	During the last five years, the Reporting Person has not been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
(e)	During the last five years, the Reporting Person has not been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
(f)	The Reporting Person is a citizen of the United States of America.
Item 3.	Source and Amount of Funds or Other Consideration
	Item 3 of the Original Schedule 13D is hereby amended and restated in its entirety as follows: The Reporting Person is filing this Amendment to report that his beneficial ownership of Common Stock has fallen below 5% of the outstanding Common Stock. This decrease in beneficial ownership percentage resulted from the dilution of the Reporting Person's holdings due to an increase in the Issuer's issued and outstanding shares of Common Stock issued as a result of the Fee Letter. No funds were used or received by the Reporting Person in connection with the decrease in his beneficial ownership percentage.
Item 4.	Purpose of Transaction
	Item 4 of the Original Schedule 13D is hereby amended and supplemented to add the following: As described in Item 5, as a result of the issuance by the Issuer of additional shares of Common Stock, and not as a result of any acquisition or disposition of securities by the Reporting Person, the Reporting Person ceased to be the beneficial owner of more than five percent of the outstanding Common Stock on August 18, 2026. Accordingly, this Amendment constitutes the final amendment to the Schedule 13D, and the Reporting Person's reporting obligations under Section 13(d) of the Act with respect to the Common Stock are terminated. The Reporting Person continues to serve as the President and Chief Executive Officer and a director of the Issuer.
Item 5.	Interest in Securities of the Issuer
(a)	Item 5 of the Original Schedule 13D is hereby amended and restated in its entirety as follows: As of the date hereof, the Reporting Person beneficially owned 3,085,519 shares of Common Stock, which represents approximately 4.6% of the outstanding shares of Common Stock, which is comprised of (i) 2,173,307 shares of Common Stock, and (ii) 912,212 shares of Common Stock issuable upon the exercise of options held by the Reporting Person which are exercisable within 60 days of the date hereof. The percentage of ownership reported in this Item 5 was calculated based on 65,758,360 shares of Common Stock outstanding as of August 18, 2026, calculated in accordance with Rule 13d-3(d)(1)(i) promulgated under the Securities Exchange Act of 1934, as amended.
(b)	As of the date hereof, the Reporting Person has sole voting and dispositive power over 3,085,519 shares of Common Stock, which includes (i) 2,173,307 shares of Common Stock, and (ii) 912,212 shares of Common Stock issuable upon the exercise of options held by the Reporting Person which are exercisable within 60 days of the date hereof.
(c)	None.
(d)	None.
(e)	As of August 18, 2026, the Reporting Person ceased to be the beneficial owner of more than 5% of the Common Stock of the Issuer. The filing of this Amendment represents the final amendment to the Original Schedule 13D and constitutes an exit filing for the Reporting Person.
Item 6.	Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
	Item 6 of the Original Schedule 13D is hereby amended and restated in its entirety as follows: None.
Item 7.	Material to be Filed as Exhibits.
	Item 7 of the Original Schedule 13D is hereby amended and restated in its entirety as follows: None.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

James A. Bianco, M.D.

Signature:	/s/ James A. Bianco, M.D.
Name/Title:	President and Chief Executive Officer
Date:	08/28/2026